A randomised, prospective phase II study of pharmacokinetics and safety aspects of higher doses of rifampicin and pyrazinamide in a shortened treatment of mild-to-moderate tuberculosis compared with standard of care
Key facts
- Where
- Linkoping és Norrkoping, SvédországSee the 2 sites
- Phase
- 2. fázis
Where in Svédország
- Region OestergoetlandLinkoping, SvédországTaking people
- Vrinnevisjukhuset I Norrkoeping Region OestergoetlandNorrkoping, SvédországTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Region Oestergoetland
- Trial code
- EU 2024-518772-32-00
- Record updated
- 2024. október 18.
- Original description
The main aim of the study is to investigate strategies for reducing the length of TB treatment through detailed study of a shorter TB treatment based on higher doses of RIF and PZA, for a selected group of patients with drug-sensitive pulmonary TB.Read full original descriptionShow less
The main aim of the study is to investigate strategies for reducing the length of TB treatment through detailed study of a shorter TB treatment based on higher doses of RIF and PZA, for a selected group of patients with drug-sensitive pulmonary TB.
Inclusion: Confirmed active pulmonary tuberculosis, through positive culture or positive PCR test for M.tuberculosis-complex; Has provided written consent; Assigned for TB-treatment (first-line drugs) but not yet started treatment.
Exclusion: Has received treatment for active TB in the past 12 months leading up to inclusion in the study; Resistance to any of the drugs (RIF, INH, PZA, EMB) included in the standard TB treatment according to molecular biological or phenotypic drug susceptibility testing.